Aevi Genomic Medicine Inc
GNMX
GNMX was delisted on the 3rd of February, 2020.
49 hedge funds and large institutions have $12.6M invested in Aevi Genomic Medicine Inc in 2017 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 7 closing their positions.
22% more capital invested
Capital invested by funds: $10.3M → $12.6M (+$2.28M)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
4% less funds holding
Funds holding: 51 → 49 (-2)
14% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 14
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$3.74M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$136K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$74.8K |
| 4 |
NCMW
Northern Capital Management (Wisconsin)
Madison,
Wisconsin
|
+$59.1K |
| 5 |
VF
Virtu Financial
New York
|
+$45.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$390K |
| 2 |
ECM
Element Capital Management
New York
|
-$165K |
| 3 |
LP
LMR Partners
London,
United Kingdom
|
-$149K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$131K |
| 5 |
Morgan Stanley
New York
|
-$62.5K |
GNMX Hedge Fund Activity: Q3 2017 in Review
49 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q3 2017, worth a combined $12.6M — up 22% from $10.3M a quarter earlier.
Fund positioning in GNMX was balanced in Q3 2017: 7 funds opened new positions, 7 closed out, 12 added to existing stakes and 14 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $3.74M. The largest seller was Goldman Sachs, cutting an estimated $390K.
- 49 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q3 2017, down from 51 in Q2 2017.
- Funds reported $12.6M of Aevi Genomic Medicine Inc stock for Q3 2017, up 22% quarter-over-quarter.
- 7 funds opened new Aevi Genomic Medicine Inc positions in Q3 2017 and 7 closed out, a net change of 0 holders.
- The largest Aevi Genomic Medicine Inc buyer in Q3 2017 was Baker Bros. Advisors, an estimated $3.74M added.
- The largest Aevi Genomic Medicine Inc seller in Q3 2017 was Goldman Sachs, an estimated $390K sold.
Based on aggregated 13F filings for Q3 2017.